摘要
目的研究哌拉西林-他唑巴坦替换第三代头孢菌素应用于神经ICU患者的临床价值,探讨其对产ESBLs菌株医院感染发生的影响。方法在哌拉西林-他唑巴坦临床干预前后,检测患者直肠拭子存在产ESBLs的大肠埃希菌,肺炎克雷伯杆菌的情况,比较前后两阶段的产ESBLs细菌的临床寄殖率;并对哌拉西林-他唑巴坦临床干预前后患者的气道分泌物进行培养鉴定、分析药物敏感性,比较前后两阶段产ESBLs细菌发生率变化。结果哌拉西林-他唑巴坦干预后,大肠埃希菌,肺炎克雷伯杆菌产ESBLs菌寄殖率从33.3%降至18.8%(P<0.05)。产ESBLs肺炎克雷伯杆菌比率从72.2%降至50%(P<0.05),产ESBLs大肠埃希菌比率从75%降至39.58%(P<0.05)。结论在神经ICU病区使用哌拉西林-他唑巴坦替换第三代头孢菌素可降低单元内产ESBLs细菌临床寄殖率,降低产ESBLs菌比率。
Objective The aim of this study was to clarify the effect of ESBL （ ＋ ） bacterium under the replacement ot third generation cephalosporin by in Neurosurgieal Intensive Care Unit. Methods We tested the quantity of ESBL （ ＋ ） bacterium （ Escherichia coli and Klebsiella pneumoniae） , and compared the rate of proliferation before and after using Piperacillin-Tazobae- tam; Likewise we cultivated the production of patients＇airway before and after using Piperacillin-Tazobactam, and the bacterium were isolated for drug sensitivity test, to analysis the rate of ESBL （ ＋ ） bacterium in these two periods. Results After using Piperaeillin- Tazobaetam, the proliferation rate of ESBL （ ＋ ） bacterium degraded from 33.3% to 18.8%. （P 〈0. 05）. The proliferation rate of ESBL （ ＋ ） Klebsiella pneumoniae decreased from 72. 2% to 50% （ P 〈 0.05 ） , this rate of ESBL （ ＋ ） Escherichia coli degraded from 72. 2% to 50% （ P 〈 0.05 ）. Conclusion Replacement of third generation cephalosporin by Piperacillin-Tazobactam could de- grade the rate of ESBL （ ＋ ） bacterium in Neurosurgical Intensive Care Unit.
出处
《中国老年保健医学》
2014年第3期45-48,共4页
Chinese Journal of Geriatric Care
基金
中华医学会科研专项基金(11030130257)
青岛市科技局基金[12-1-3-5-(1)-nsh]
